PDA

Pentadeca Arginate / BPC-157 arginate salt

PDA (Pentadeca Arginate / BPC-157 arginate salt) is a healing & recovery research compound. The BPC-157 pentadecapeptide supplied as an arginate salt rather than the usual acetate. The sequence, and therefore the mechanism, is the same: VEGFR2 and nitric-oxide signaling driving angiogenesis, with the growth-factor upregulation behind the tendon, gut, muscle and nerve repair BPC-157 is known for. What the arginate counter-ion changes is the physical chemistry of the salt, and vendors market it as the more stable of the two. That is a formulation claim, not a potency claim: nobody has published a head-to-head of arginate against acetate in a living system.

How PDA works

The BPC-157 pentadecapeptide supplied as an arginate salt rather than the usual acetate. The sequence, and therefore the mechanism, is the same: VEGFR2 and nitric-oxide signaling driving angiogenesis, with the growth-factor upregulation behind the tendon, gut, muscle and nerve repair BPC-157 is known for. What the arginate counter-ion changes is the physical chemistry of the salt, and vendors market it as the more stable of the two. That is a formulation claim, not a potency claim: nobody has published a head-to-head of arginate against acetate in a living system.

Proposed benefits

Tendon, gut and soft-tissue repair — the BPC-157 peptide as an arginate salt, sold on shelf stability rather than a different mechanism.

Where to get PDA

PDA is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.

The evidence for PDA

Graded by what exists behind each claim.

✅ Clinically validated

• No human trial of PDA exists, and none of BPC-157 either. PDA is the same pentadecapeptide supplied as an arginate salt, so it inherits BPC-157's evidence position exactly: strong animal work, no completed randomized human efficacy trial, and a 2023 FDA move to bulk-substances category 2 that restricts compounding — a judgement about missing data, not a finding of harm.
• Nothing compares the two salts in a living system. The arginate is marketed as more stable. Stability is a property of the powder in the vial; it is not a claim about what happens after injection, and no published work bridges the two.

📊 Correlative data

• The anecdotal record people cite for PDA is BPC-157's record, because the peptide is the same. That record is large and it is also the clearest case in the Vault of anecdote being a weak instrument: soft-tissue injuries and gut flares resolve on their own, so anything taken during recovery collects the credit.
• PDA's own anecdotal history is short — it entered the research market recently, and reports specific to the arginate salt are too few and too new to separate from BPC-157's.

🧪 Theoretical / extrapolated

• Identical to BPC-157 by definition: VEGFR2 and nitric-oxide signaling driving angiogenesis, with growth-factor upregulation behind tendon, gut, muscle and nerve repair. A counter-ion changes the salt's physical chemistry, not the peptide's sequence or its receptor interactions.
• The mechanistic argument FOR the arginate is pharmacokinetic — a more stable salt could mean more intact peptide surviving to the point of action. Plausible, unmeasured, and worth treating as a hypothesis rather than a feature.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What PDA actually does

Start with what an arginate salt is, because that is the only thing distinguishing this page from the BPC-157 page, and the answer is smaller than the marketing suggests. A peptide with free carboxyl groups can be isolated as a salt with any suitable counter-ion. Acetate is the standard because it is the residue of the trifluoroacetate-to-acetate exchange at the end of solid-phase synthesis. Arginate substitutes arginine, itself a basic amino acid, as the counter-ion. A salt dissociates in aqueous solution. Once the vial is reconstituted, what is in the syringe is the same 15-residue peptide, plus acetate ions or plus arginine, and the peptide that meets the tissue is identical in both cases.

So what CAN a counter-ion change? Three real things, all physical. The hygroscopicity and shelf stability of the lyophilized powder; the pH of the reconstituted solution, which for an arginine counter-ion is higher and may reduce the sting; and the solubility profile. What it cannot change is the sequence, the receptor engagement, the plasma clearance, or the potency per microgram of peptide. Those are properties of the peptide, and the peptide is the same. A stability claim about a powder is not a potency claim about a person, and nobody has published a head-to-head of arginate against acetate in a living system.

Now the peptide itself, and the honest starting point is that it has no identified receptor. The 15-residue sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val is derived from a fragment of human gastric juice protein. It is not a ligand for any cloned receptor. That is unusual and it constrains what can honestly be claimed: a peptide with no receptor is a peptide whose mechanism is described by the pathways that move when it is given, not by a binding event anyone has measured.

What does move, consistently, across a large rodent literature. The nitric oxide system — the effects are reported to be modulated by L-NAME and L-arginine, which is the classic pharmacological signature of NO involvement. VEGF receptor 2 signaling and angiogenesis. Growth factor expression in healing tissue. The claimed range spans gut, tendon, muscle, nerve, vessel and brain Sikiric 2020 Sikiric 2022 Sikiric 2023 Staresinic 2022. The breadth of that list is itself a finding, and it can be read two ways: a genuinely upstream cytoprotective mechanism, or a signal that the assays are non-specific. Both readings are live and the page should say so.

Cell, rodent, human — and where it stops

Step one, cells and rodents, where the volume of work is large. Rat models of ischemia-reperfusion injury, major vessel occlusion and Budd-Chiari syndrome Sikiric 2022; rat spinal cord injury with recovery reported after peptide administration Perovic 2022; striated, smooth and cardiac muscle Staresinic 2022; the brain-gut axis Sikiric 2023. The cytoprotection framework these sit inside has been developed over decades Sikiric 2020.

Step two, the fact about that literature a reader is owed. The overwhelming majority of it comes from one research group. That is not an accusation and it does not make the work wrong; it is a structural feature of the evidence base, and it means the missing ingredient is independent replication rather than sample size. For any compound, a body of work from a single group is a different epistemic situation from the same number of papers from twenty groups, and a research site should name which one it is looking at.

Step three, humans. There is no randomized controlled trial of BPC-157 for any indication, in either salt form. Not for gut healing, not for tendon, not for anything. The human record is anecdote and clinic reports.

Step four, the obstacle specific to THIS page, and it is absolute. Everything above is about BPC-157 as studied, which means the acetate. There is not one published experiment comparing the arginate salt to the acetate in a cell, an animal or a person. Zero. The transfer from the BPC-157 literature to this page rests entirely on the chemical argument that a dissociated salt delivers the same peptide — which is sound chemistry and is not a measurement.

PDA pharmacokinetics — how much of it actually gets in

The card prints ~4 hours systemic, carried over from BPC-157. There is now a real pharmacokinetic study of this peptide, and its number is different by roughly an order of magnitude.

The measurement. A dedicated study of the pharmacokinetics, distribution, metabolism and excretion of BPC-157 in rats and dogs found an elimination half-life of less than 30 minutes, mean absolute bioavailability of approximately 14–19% in rats and 45–51% in beagle dogs after intramuscular injection, and linear pharmacokinetics across doses He 2022. Under 30 minutes, not four hours. That is the only quantitative pharmacokinetic dataset this peptide has in any species, and this page is where the Vault should say so.

What degrades it, and why the number is unsurprising. A 15-residue peptide with free N- and C-termini is exposed to aminopeptidases and carboxypeptidases in plasma and on endothelium, and to endopeptidases throughout. Enzymatic hydrolysis, not cytochrome metabolism, is the clearance route; the products are shorter fragments and free amino acids. The five prolines in the sequence are a genuine structural defense — proline residues resist many endopeptidases — which is probably why it survives minutes rather than seconds.

The oral barrier, and the claim it complicates. This compound is widely sold in an oral form, and the Vault card lists one. An oral peptide meets pepsin, then trypsin and chymotrypsin, then brush-border aminopeptidases, before first-pass metabolism is even relevant. The intramuscular bioavailability figures above He 2022 are for injection; no oral bioavailability figure has been published for this peptide at all, which means the oral form's dose has no measured relationship to the injectable one. If the oral form works, the most plausible mechanism is local action on gut tissue rather than systemic exposure — and that is a genuinely different claim from the one usually made for it.

What a sub-30-minute half-life implies for scheduling. If the systemic exposure is gone within an hour and the reported effects take weeks, then exposure and effect are on completely different timescales, exactly as they are for a growth-factor signal rather than for a receptor occupancy. Dosing chosen to “keep levels up” is answering the wrong question. It also means the local concentration at an injection site, which is orders of magnitude above plasma, is plausibly where the action is — which is the mechanistic argument for injecting near the target tissue, and it has never been tested against a distant site.

What would have to be true, and how you would know it was not

Three predictions. The first is the one that would settle the arginate question; the third argues against the way the compound is usually judged.

1. Arginate and acetate should be indistinguishable in a person, and that is falsifiable with an ordinary blood draw. If a salt dissociates and delivers the same peptide, then the same microgram dose of each should produce the same plasma peptide concentration-time curve. Four timed draws after each, a week apart, in one person, with a peptide assay. Prediction: identical curves. If the arginate curve is higher or longer, the stability claim has a pharmacokinetic consequence and the whole product category has its first piece of supporting evidence. Nobody has run this and it is the cheapest decisive experiment on the page.

2. Systemic inflammatory markers should not move, and a rise means something else is in the vial. Draw hs-CRP and ESR at baseline and 6 weeks. Prediction: unchanged. The claimed mechanism is local tissue repair, not systemic immunomodulation, so a rise in either marker on a research-grade peptide points at an injection-site reaction or at contamination rather than at pharmacology. That makes hs-CRP a purity check as much as an efficacy one.

3. The prediction that cuts against the usual read: healing will improve on its own timeline and the peptide will get the credit. Most soft-tissue injuries improve over 6–12 weeks without intervention, which is the same window over which people run this peptide. The falsifiable version needs a measurement that is not a feeling: grip strength for an upper-limb injury, or a fixed, timed, load-matched movement test recorded weekly, starting two weeks before the first injection. The pre-injection slope is the control. If the trajectory does not change at the moment of starting, the peptide did not do it — and almost nobody collects the two weeks that make the comparison possible.

What nobody has tested yet

Four experiments, and the first two are specific to the arginate salt this page is about.

Nobody has run any head-to-head of arginate against acetate. Not in a cell, not in a rat, not in a person, on any endpoint. The entire premium this product commands rests on a formulation claim with no comparative data of any kind.

Nobody has published a stability dataset for either salt. The claim is that arginate is more stable. Peptide stability under defined temperature and humidity is a routine, inexpensive, regulated assay reported for every approved peptide drug. For this one it has never been published, so the marketing claim and its rebuttal are equally unevidenced.

Nobody has measured oral bioavailability. The injectable figures exist for two species He 2022. The oral figure does not exist for any species, and an oral form is sold. Establishing whether an oral dose produces any systemic peptide at all would either validate a large part of the market or redirect it toward a gut-local claim.

Nobody outside one research group has tried to replicate the core findings. The tendon and gut results are the ones people buy this for Sikiric 2020 Staresinic 2022. An independent laboratory repeating one rat tendon-healing experiment, blinded, would be the single highest-value study anyone could run on this molecule, and after three decades it has still not appeared.

PDA — its own safety story, not its class's

The honest safety statement for this compound is unusual: the documented toxicity is very low and the documented human safety data is zero, and those are two different sentences.

What the animal record shows. Across a large rodent literature the peptide is described as well tolerated with no identified toxic dose, and the pharmacokinetic study that measured distribution and excretion in rats and dogs did not report a toxicity signal He 2022 Sikiric 2020. For a compound this widely used, that record is genuinely reassuring as far as it goes.

What is missing is not reassurance but data. There has never been a human clinical trial, so there is no adverse event rate, no long-term exposure data, and no answer to the one theoretical concern the mechanism raises: a peptide that promotes angiogenesis through VEGF receptor 2 signaling is a peptide whose effect on an existing malignancy is unknown, because tumors also require blood vessels. Nobody is claiming it causes cancer. Nobody has looked, and a page that lists angiogenesis as a benefit owes the reader that sentence.

The risk that is specific to the arginate form. Arginine as a counter-ion raises the pH of the reconstituted solution relative to acetate. That plausibly reduces the sting of injection, and it also means a solution whose pH is further from the acetate-buffered norm — which matters if it is mixed in the same syringe with another peptide that is acetate-buffered and pH-sensitive. Mixing compounds with different counter-ions in one syringe is a formulation decision nobody has data for, and this salt is exactly the case where it comes up.

And the supply risk, which for this molecule is the main one. The identity of a 15-residue peptide is verifiable by mass spectrometry and essentially no buyer does it. Sold as arginate, a vial cannot be distinguished from the same peptide as acetate by anything a purchaser can observe — same white powder, same reconstitution, same result — which makes this the one compound in the Vault whose premium feature is invisible even in principle without an analytical laboratory. This is education about the chemistry, not a recommendation for use.

Sources read for this page

• He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology 2022 · PMID 36588717
• Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver 2020 · PMID 31158953
• Sikiric P, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World Journal of Gastroenterology 2022 · PMID 35125818
• Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel) 2023 · PMID 37242459
• Perovic D, et al. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy. Current Issues in Molecular Biology 2022 · PMID 35678659

PDA — interference & stacking

Bloodwork to run alongside PDA

Baseline first, then again at 8–12 weeks.

The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.

Check results you already have → · All 103 markers A–Z

PDA — frequently asked questions

What PDA is used for

PDA appears under 2 goals in the goal router.

Related Healing & Recovery compounds

← Explore the full Protocol Vault

↑ Back to on this page